SEC Form 4 · accession 0001127602-18-015184
Cibus, Inc. · CBUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel F Voytas
Officer — Chief Science Officer
Period of report
Apr 20, 2018
Accepted (ET)
Apr 24, 2018 · 6:13 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001705843
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Apr 20, 2018 | M | 4,666 | $3.59 | A | 105,187 | D | |
| Common StockF3,F1 | Apr 20, 2018 | S | 4,666 | $16.8669 | D | 100,521 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $3.59 | Apr 20, 2018 | M | 4,666 | D | — | Apr 7, 2026 | Common Stock | 4,666 | 235,668 | D |
Explanation of responses
- F1Includes 100,521 restricted stock units with respect to Calyxt, Inc. common stock, which were granted on June 14, 2017 and vest 15% on the first anniversary of the grant date and 15% on the second anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2017.
- F3The price reported in Column 4 is weighted average price. These shares were sold in multiple transactions at prices ranging from $16.7001-$16.92, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- F4The Stock Option was granted on April 7, 2016 and vests 20% on the grant date and 10% on the first anniversary of the grant date, with the remainder vesting quarterly in equal installments over the following 42 months (or with an additional 25% vesting immediately if Calyxt, Inc. undergoes a change in control, liquidation, dissolution or initial public offering and the remainder vesting quarterly thereafter).